![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
University Hospital Tuebingen Dr. Falk Pharma GmbH Principal Investigator: Univ. Hosp. Tuebingen, Dept. of Clinical Pharmacology |
Information provided by: | University Hospital Tuebingen |
ClinicalTrials.gov Identifier: | NCT00338910 |
The primary objective of this study is to describe a possible effect of metronidazole on PK of budesonide in healthy volunteers.
Condition | Intervention | Phase |
Healthy |
Drug: Budesonide 2 single doses, Metronidazole multiple-dose |
Phase IV |
ChemIDplus related topics: | Metronidazole Metronidazole hydrochloride Metronidazole phosphate Budesonide |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | Pharmacokinetic Interaction Study Between Budesonide and Metronidazole in Healthy Volunteers |
Enrollment: | 12 |
Study Start Date: | May 2006 |
Study Completion Date: | June 2006 |
The primary objective of this study is to describe a possible effect of metronidazole on PK of budesonide in healthy volunteers.
Secondary objectives:
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
University Hospital Tuebingen |
Dr. Falk Pharma GmbH |
Principal Investigator: Univ. Hosp. Tuebingen, Dept. of Clinical Pharmacology |
Principal Investigator: | Christoph H Gleiter, MD | Department of Clinical Pharmacology |
Study ID Numbers: | BUC-58/BIO |
First Received: | June 19, 2006 |
Last Updated: | December 10, 2007 |
ClinicalTrials.gov Identifier: | NCT00338910 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
|
|
|
![]() |